Novartis AG is aiming to launch 10 potential blockbusters by 2020 but for the moment, the Swiss major is reaping the benefits from an established big seller – Cosentyx (secukinumab) – which is continuing to grow at an impressive rate.
Speaking at Novartis' annual press conference in Basel on Jan. 30, chief executive Vas Narasimhan highlighted how much of a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?